UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38594 TILRAY BRANDS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4310622 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38594 TILRAY BRANDS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4310622 (State or other jurisdict ...

Tilray Brands, Inc. (NASDAQ:TLRY) Q2 2023 Results Conference Call January 9, 2023 8:30 AM ET Company Participants Berrin Noorata - Chief Corporate Affairs Officer Irwin Simon - Chairman and Chief Executive Officer Carl Merton - Chief Financial Officer Denise Faltischek - Chief Strategy Officer and Head, International Blair MacNeil - President, Tilray Canada Ty Gilmore - President, U.S. Beer Business Conference Call Participants Victor Ma - Cowen & Company Nadine Sarwat - Bernstein Andrew Carter - Stifel Aar ...

Table of Contents Commission File Number: 001-38594 TILRAY BRANDS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact Name of Registrant as Specified in its Charter) Delaware 82-4310622 (State or ...

Financial Data and Key Metrics Changes - Net revenue in Q1 was $153.2 million, a 9% decline compared to the prior year quarter of $168 million, largely due to brand and SKU rationalization and foreign currency rates [61] - Reported gross profit was $48.6 million in Q1, a 5% decrease from $51 million in the prior year quarter, while adjusted gross margin increased 200 basis points to 32% from 30% [63] - Net loss was $65.8 million in Q1 compared to a net loss of $34.6 million in the prior year quarter, but adjusted EBITDA was $13.5 million, up 7% from the prior year quarter [64] Business Line Data and Key Metrics Changes - Revenue in the cannabis segment was $58.6 million, with Canadian adult-use revenue impacted by price compression and operational challenges, but increased 10% from the preceding quarter [68][69] - International cannabis revenue increased 2% to $10.4 million, but would have increased 16% on a constant currency basis [71] - Beverage alcohol segment generated $20.7 million in net revenue, a 34% increase from the prior year quarter, primarily due to the acquisition of Breckenridge [76] Market Data and Key Metrics Changes - In Canada, the company grew its market share position nationally by 8 basis points to 8.5% for the quarter, leading competitors HEXO and Organigram [47] - In Germany, the company holds approximately a 20% market share across flower, extracts, and Dronabinol products, with revenue up 22% versus the prior year period [36][37] - The European market for cannabis is estimated to be worth as much as $37 billion by 2027, with significant momentum towards adult-use legalization [18] Company Strategy and Development Direction - The company is focused on optimizing global operations and has targeted over $100 million in cash cost savings, with $95 million already realized [11][12] - The strategic alliance with HEXO is expected to deliver $40 million, including $31 million in revenue and $9 million in interest over the fiscal year [15] - The company aims to leverage its strong balance sheet and operational efficiencies to capture market share across the global cannabis industry [15][84] Management's Comments on Operating Environment and Future Outlook - Management noted that the current macro environment is challenging, but the company is well-positioned to capitalize on growth opportunities in Canada, Europe, and the U.S. [8][20] - The company anticipates delivering significant growth in adjusted EBITDA to between $70 million and $80 million in fiscal 2023, representing up to 67% growth compared to fiscal 2022 [16][84] - Management expressed optimism about the potential for adult-use legalization in Germany and the broader European market, which could significantly enhance growth prospects [19][38] Other Important Information - The company has approximately $500 million in cash and $638 million in working capital, with over 70% of its debt set at fixed interest rates [15] - The company is launching new products in its wellness segment, including culinary oils and plant-based protein blends, and has signed a distribution agreement for its CBD beverage portfolio [30][29] Q&A Session All Questions and Answers Question: U.S. regulatory landscape and opportunities - Management acknowledged the Biden administration's recent actions as a positive sign for the cannabis industry and emphasized the company's strong cash position and growth opportunities in Canada and internationally [90][92] Question: Down-trading in alcohol assets and pricing backdrop - Management reported no signs of down-trading in their alcohol assets and noted good consumption within the beer business, while also preparing for potential shifts in consumer behavior [96][97] Question: Recreational legalization in Germany - Management expressed confidence in the legalization of cannabis in Germany, highlighting the company's investments in facilities that can quickly adapt to the adult-use market [106][110]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38594 TILRAY BRANDS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organiza ...

Tilray Brands, Inc. (NASDAQ:TLRY) Q4 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Berrin Noorata - Chief Corporate Affairs Officer Irwin Simon - Chairman & Chief Executive Officer Denise Faltischek - Chief Strategy Officer & Head-International Business Blair MacNeil - President-Canada Carl Merton - Chief Financial Officer Conference Call Participants Victor Ma - Cowen & Co. Andrew Carter - Stifel Aaron Grey - Alliance Global Partners Tamy Chen - BMO Capital Markets John Zampar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38594 TILRAY BRANDS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...

Tilray Brands, Inc. (NASDAQ:TLRY) Q3 2022 Earnings Conference Call April 6, 2022 8:30 AM ET Company Participants Irwin Simon - Chairman and CEO Carl Merton - CFO Denise Faltischek - Chief Strategy Officer and Head, International Blair MacNeil - President, Tilray Canada Berrin Noorata - Chief Corporate Affairs Officer Conference Call Participants Gerald Pascarelli - Cowen Andrew Carter - Stifel Owen Bennett - Jefferies Rupesh Parikh - Oppenheimer John Zamparo - CIBC Aaron Grey - Alliance Global Partners Scot ...

Tilray, Inc. (NASDAQ:TLRY) Q2 2022 Earnings Conference Call January 10, 2022 8:30 AM ET Company Participants Berrin Noorata - Chief Corporate Affairs Officer Irwin Simon - Chairman and Chief Executive Officer Blair MacNeil - President, Canada Denise Faltischek - Head of International and Chief Strategy Carl Merton - Chief Financial Officer Conference Call Participants Vivien Azer - Cowen and Company Andrew Carter - Stifel Financial Pablo Zuanic - Cantor Fitzgerald Rupesh Parikh - Oppenheimer & Co. John Zamp ...